- Tryp Therapeutics has partnered with Dr. Paul Hutson and Dr. Christopher Nicholas, researchers at the University of Wisconsin-Madison
- The collaboration will focus on a clinical pharmacology studies to evaluate the safety and pharmacokinetics of TRP-8803, Tryp’s proprietary drug formulation
- The partnership is the latest in a series of collaborations as the company prepares for Phase 2b trials
- Tryp intends to use data from its Phase 2a clinical studies, expected to launch this year, coupled with preclinical data and clinical pharmacology data for TRP-8803, to support the use of the novel drug formulation in Phase 2b trials
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a company leading the next wave of psychedelics beyond mental health and unleashing the full potential of psilocybin for conditions with unmet needs, recently announced a collaboration with researchers at the University of Wisconsin-Madison, as part of preparations toward the planned Phase 2b studies (https://nnw.fm/QOkJ2).
Under the partnership, Dr. Paul Hutson, PharmD, a Professor of the Pharmacy Practice Division at the University of Wisconsin-Madison School of Pharmacy, and Dr. Christopher Nicholas, PhD, an Assistant Professor at the University of Wisconsin-Madison School of Medicine and Public Health, will support clinical pharmacology studies for TRP-8803, Tryp’s proprietary drug formulation with a novel route of administration. Once completed, the studies will provide additional regulatory support for TRP-8803.
The pair will also serve as investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803 in healthy, volunteer patients.
Dr. Hutson, who has been the Principal Investigator for a safety and dose-escalation clinical trial for psilocybin performed at the university, brings a wealth of experience assessing the therapeutic uses of psilocybin and other psychoactive medications.
Similarly, Dr. Nicholas, a trained clinical psychologist and neuroscientist with expertise in psychedelic-assisted therapy, brings extensive clinical trial-related experience, having served as the Principal Investigator on several psilocybin clinical trials and mechanistic studies. As Tryp’s partner, he will offer guidance on study design, behavioral and biological outcome measures, and psychological support to ensure participants will successfully complete the pharmacology study.
This partnership is the latest in a series of collaborations with scholars, institutions, and companies, as Tryp prepares for its Phase 2b clinical studies.
In July, Tryp announced an agreement with the University of Michigan as part of upcoming bridging studies designed to grow its IP portfolio for TRP-8803 and facilitate the drug formulation’s advancement into Phase 2b trials (https://nnw.fm/QFPBb).
Later, in August, Tryp announced partnerships with Calvert Labs – an Altasciences company – and Gad Consulting Services. Under the terms of the agreement, Calvert Labs will design and execute exploratory bridging studies to generate toxicology and blood exposure level data for TRP-8803, while Gad Consulting will advise on specific aspects of these studies. Tryp will then work with Altasciences to perform clinical pharmacology studies in healthy, volunteer patients (https://nnw.fm/9cInz).
The latest collaboration with researchers from the University of Wisconsin-Madison, therefore builds on the diligence that Tryp is completing through the Altasciences partnership on clinical pharmacology studies.
Tryp has also made substantial strides toward the expected launch of the Phase 2a clinical studies to evaluate TRP-8802, a non-proprietary oral formulation of synthetic psilocybin. The company recently achieved its most important milestone yet when it submitted to the FDA an Investigational New Drug (“IND”) application to evaluate the oral formulation (https://nnw.fm/3x8tj).
Using TRP-8802 for its Phase 2a studies allows the company to quickly initiate its clinical trials as it determines the effectiveness of psilocybin for its target indications, which include eating disorders such as binge eating disorder and hypothalamic obesity, and chronic pain disorders such as fibromyalgia, phantom limb pain, and CRPS.
Tryp intends to use the data generated through the Phase 2a studies, combined with preclinical data for TRP-8803 and clinical pharmacology data from studies – including those supported by Dr. Hutson and Dr. Nicholas – to back the use of TRP-8803 in Phase 2b trials and beyond as well as in eventual commercialization (https://nnw.fm/EHvcL).
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://nnw.fm/TRYPF
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.